Neurol. praxi. 2024;25(5):357-361 | DOI: 10.36290/neu.2024.015

Cardiovascular adverse effects of neurological and psychiatric drugs

MUDr. Václav Boček, Ph.D.1, PharmDr. Kristina Pechandová, Ph.D.2
1 Neurologické oddělení Nemocnice Strakonice, a. s.
2 Klinický farmaceut Nemocnice Strakonice, a. s.

With increasing pharmacotherapeutic options, the spectrum of adverse effects and drug interactions of individual drugs used in neurology is expanding. Cardiovascular adverse effects and drug interactions are among the frequent and potentially life-threatening conditions that can be prevented by correctly indicating individual medicinal products. The present review article focuses on providing an account of basic drug-induced complications, such as arterial hypertension, orthostatic hypotension, cardiac conduction disorders, myocardial ischaemia, and cardiomyopathy. It also deals, to a lesser extent, with interactions of neurological drugs with cardiological medicinal products. The goal of any pharmacotherapy should be the most reasonable strategy, achieved with the least possible number of products while taking into consideration the patient's individual circumstances. Interdisciplinary collaboration, including a cardiologist and a clinical pharmacologist or pharmacist, plays an important role here.

Keywords: neurocardiology, neuropharmacology, adverse effects, drug interactions, rational pharmacotherapy.

Received: December 8, 2023; Revised: February 14, 2024; Accepted: March 4, 2024; Prepublished online: March 4, 2024; Published: November 19, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Boček V, Pechandová K. Cardiovascular adverse effects of neurological and psychiatric drugs. Neurol. praxi. 2024;25(5):357-361. doi: 10.36290/neu.2024.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 19.11.2025

    References

    1. Ali TB, Schleret TR, Reilly BM, et al. Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United­‑States and Canada. PLoS One. 2015;10(12):e0144337. doi: 10.1371/journal.pone.0144337. PMID: 26642212; PMCID: PMC4671709. Go to original source... Go to PubMed...
    2. Al­‑Yafeai Z, Carvajal­‑González A, Abduljabar H, et al. Novel multiple sclerosis agents­‑associated cardiotoxicity: A real­‑world pharmacovigilance study. Int J Cardiol. 2022;362:153-157. doi: 10.1016/j.ijcard.2022. 05. 052. Epub 2022 May 26. PMID: 35643216. Go to original source...
    3. Beach SR, Celano CM, Sugrue AM, et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018;59(2):105-122. doi: 10.1016/j.psym.2017. 10. 009. Epub 2017 Nov 3. PMID: 29275963. Go to original source...
    4. Berger SI, Iyengar R. Role of systems pharmacology in under­standing drug adverse events. Wiley Interdiscip Rev Syst Biol Med. 2011;3(2):129-35. doi: 10.1002/wsbm.114. Go to original source... Go to PubMed...
    5. Ceron C, Goyal A, Makaryus AN. Drug­‑Induced Valvular Heart Disease. 2023 Jul 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. PMID: 29262190.
    6. Edinoff AN, Nguyen LH, Fitz­‑Gerald MJEt al. Lamotrigine and Stevens­‑Johnson Syndrome Prevention. Psychopharmacol Bull. 2021;51(2):96-114. PMID: 34092825; PMCID: PMC8146560.
    7. Espay AJ, LeWitt PA, Hauser RA, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synuclei­‑nopathies: prioritisation of treatment targets. Lancet Neurol. 2016;15(9):954-66. Go to original source... Go to PubMed...
    8. Grossman A, Messerli FH, Grossman E. Drug induced hypertension - An unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015;763(Pt A):15-22. doi: 10.1016/j.ejphar.2015. 06. 027. Epub 2015 Jun 19. PMID: 26096556. Go to original source...
    9. Guldiken B, Rémi J, Noachtar S. Cardiovascular adverse effects of phenytoin. J Neurol. 2016;263(5):861-870. doi: 10.1007/s00415-015-7967-1. Epub 2015 Dec 8. PMID: 26645393. Go to original source... Go to PubMed...
    10. Hoffmann F, van den Bussche H, Wiese B et al. Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia. BMC Psychiatry. 2011;11:190. doi: 10.1186/1471-244X-11-190. PMID: 22145796; PMCID: PMC3262154. Go to original source... Go to PubMed...
    11. Chai PY, Chang CT, Chen YH, Chen HY, Tam KW. Effect of drug interactions between carbapenems and valproate on serum valproate concentration: a systematic review and meta­‑analysis. Expert Opin Drug Saf. 2021;20(2):215-223. doi: 10.1080/14740338.2021.1865307. Epub 2020 Dec 28. PMID: 33322967. Go to original source... Go to PubMed...
    12. Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol. 2013;76(1):48-57. doi: 10.1111/bcp.12040. PMID: 23167578; PMCID: PMC3703227. Go to original source... Go to PubMed...
    13. Jia L, Eroglu TE, Wilders R, et al. Carbamazepine Increases the Risk of Sudden Cardiac Arrest by a Reduction of the Cardiac Sodium Current. Front Cell Dev Biol. 2022;10:891996. doi: 10.3389/fcell.2022.891996. PMID: 35721495; PMCID: PMC9204209. Go to original source... Go to PubMed...
    14. Lima B, Razmjouei S, Bajwa MT, et al. Polypharmacy, Gender Disparities, and Ethnic and Racial Predispositions in Long QT Syndrome: An In­‑Depth Review. Cureus. 2023;15(9):e46009. doi: 10.7759/cureus.46009. PMID: 37900391; PMCID: PMC10600617. Go to original source... Go to PubMed...
    15. Manolis TA, Manolis AA, Manolis AS. Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale. Angiology. 2019;70(2):103-129. doi: 10.1177/0003319718780145. Epub 2018 Jun 6. PMID: 29874922. Go to original source... Go to PubMed...
    16. Rommer PS, Zettl UK. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert Opin Pharmacother. 2018;19(5):483-498. doi: 10.1080/14656566.2018.1446944. Epub 2018 Mar 12. PMID: 29528247. Go to original source... Go to PubMed...
    17. Shao W, Ayub S, Drutel R, et al. QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross­‑Sectional Study of Adult Inpatients. J Clin Psychopharmacol. 2019;39(1):72-77. doi: 10.1097/JCP.0000000000000992. PMID: 30531476. Go to original source... Go to PubMed...
    18. Sicouri S, Antzelevitch C. Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Arrhythm Electrophysiol Rev. 2018;7(3):199-209. doi: 10.15420/aer.2018. 29. 2. PMID: 30416734; PMCID: PMC6141916. Go to original source...
    19. Spoelhof B, Farrokh S, Rivera­‑Lara L. Drug Interactions in Neurocritical Care. Neurocrit Care. 2017;27(2):287-296. doi: 10.1007/s12028-016-0369-0. PMID: 28054285. Go to original source... Go to PubMed...
    20. Stillman MJ, Tepper S, Tepper DE, et al. QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: review of serotonergic cardiac adverse events with a triptan case. Headache. 2013;53(1):208-216. doi: 10.1111/j.1526-4610.2012.02300.x. Epub 2012 Dec 6. Erratum in: Headache. 2013 Mar;53(3):579-80. PMID: 23216317. Go to original source... Go to PubMed...
    21. Stillman MJ, Tepper DE, Tepper SJ, et al. QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 2: review of headache medications, drug­‑drug interactions, QTc prolongation, and other arrhythmias. Headache. 2013;53(1):217-224. doi: 10.1111/j.1526-4610.2012.02299.x. Epub 2012 Dec 6. PMID: 23216298. Go to original source... Go to PubMed...
    22. Yadav R, Schrem E, Yadav V, et al. Lacosamide­‑Related Arrhythmias: A Systematic Analysis and Review of the Literature. Cureus. 2021;13(12):e20736. doi: 10.7759/cureus.20736. PMID: 35111429; PMCID: PMC8790938. Go to original source... Go to PubMed...
    23. Vazquez SR. Drug­‑drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood. 2018;132(21):2230-2239. doi: 10.1182/blood-2018-06-848747. PMID: 30463993. Go to original source... Go to PubMed...
    24. Wang J, Huang P, Yu Q, et al. Epilepsy and long­‑term risk of arrhythmias. Eur Heart J. 2023;44(35):3374-3382. doi: 10.1093/eurheartj/ehad523. PMID: 37602368; PMCID: PMC10499547. Go to original source... Go to PubMed...
    25. Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409-31. doi: 10.1684/epd.2014.0714. PMID: 25515681. Go to original source... Go to PubMed...
    26. Zhou JY, Martinez JA, Shen JP. Lamotrigine­‑induced hemophagocytic lymphohistiocytosis with Takotsubo cardiomyopathy: a case report. J Med Case Rep. 2019;13(1):345. doi: 10.1186/s13256-019-2295-1. PMID: 31767022; PMCID: PMC6878683. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.